Recent Updates
Recently added Catalysts
CRSP

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

Friday, November 9, 2018 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension

Full Press Release Details

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology.
ShareAdd on Google
Tags: CRSP Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 9, 2018

Biotech snapshot

Cash runway
$2364M liquidity · $28M/mo burn
~84 mo
Minimal dilution risk
Lead asset
CTX340Phase 1
Hypertension →

Catalyst track record

+60%
best trade around CRSP's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for CRSP.

See every catalyst's timing & PoA →